Naloxegol + Placebo Oral Capsule
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Opioid-Induced Disorders
Conditions
Opioid-Induced Disorders, Esophagus Disorder
Trial Timeline
Jan 1, 2017 → Oct 1, 2018
NCT ID
NCT02998606About Naloxegol + Placebo Oral Capsule
Naloxegol + Placebo Oral Capsule is a phase 2 stage product being developed by AstraZeneca for Opioid-Induced Disorders. The current trial status is terminated. This product is registered under clinical trial identifier NCT02998606. Target conditions include Opioid-Induced Disorders, Esophagus Disorder.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02998606 | Phase 2 | Terminated |
Competing Products
20 competing products in Opioid-Induced Disorders
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Naldemedine + Placebo | Shionogi | Approved | 85 |
| Naldemedine | Shionogi | Phase 1/2 | 41 |
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Placebo + Naldemedine | Shionogi | Phase 2 | 52 |
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Naloxegol | Kyowa Kirin | Pre-clinical | 23 |
| NKTR-118 + NKTR-118 + Placebo | AstraZeneca | Phase 3 | 77 |
| NKTR-118 + Usual care | AstraZeneca | Phase 3 | 77 |
| NKTR-118 + NKTR-118 + Placebo | AstraZeneca | Phase 3 | 77 |
| NKTR-118 + NKTR-118 + Placebo | AstraZeneca | Phase 3 | 77 |
| NKTR-118 + NKTR-118 + Placebo | AstraZeneca | Phase 3 | 77 |
| CB-5945 + Placebo | Merck | Phase 3 | 77 |
| CB-5945 + Placebo | Merck | Phase 3 | 77 |
| CB-5945 + Placebo | Merck | Phase 3 | 77 |
| CB-5945 + Placebo | Merck | Phase 3 | 77 |
| Tegaserod | Novartis | Phase 3 | 77 |
| Tegaserod | Novartis | Phase 3 | 77 |
| Methylnaltrexone bromide + Placebo | Pfizer | Phase 2 | 51 |
| ALKS 37 + Placebo | Alkermes | Phase 2 | 49 |